Latest News and Press Releases

OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)

BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has...

BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has...

Tisento's global Phase 2b PRIZM study, which is evaluating zagociguat for the treatment of the rare mitochondrial disease MELAS, is fully enrolled

Company strengthens its late-stage trials with enhanced clinical and commercial leadership for its BPM31510 programs

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its...

BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development.The Company plans to seek guidance in Q3 2025 from...

BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025

BPGbio highlights groundbreaking data on BPM31510 illustrating it's therapeutic impact as a potential treatment for primary CoQ10 deficiency.

The first patient has been dosed in Tisento's global Phase 2b PRIZM study investigating zagociguat in MELAS.